Duloxetine Hydrochloride Capsule, Delayed Release
Product Images NDC 62332-279

Product Visual Gallery

This gallery contains 14 technical images submitted to the FDA as part of the official labeling for Duloxetine Hydrochloride (NDC 62332-279). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Alembic Pharmaceuticals Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Duloxetine-structure (Duloxetine Structure)

Chemical structure diagram of the active ingredient Duloxetine in DULOXETINE HYDROCHLORIDE capsules. The schematic shows molecular bonds and key groups including a thiophene ring, naphthalene structure, and methylated amine with hydrochloride salt.*

FDA Label Image

Duloxetine-fig1.jpg (Duloxetine Fig1)

A line graph comparing the proportion of patients with relapse over time, showing two treatment groups: Duloxetine and placebo. The x-axis represents time from randomization to relapse in days (0 to 250), and the y-axis shows the proportion of patients with relapse (0 to 1). The graph indicates differences in relapse rates between the two groups over the study period.*

FDA Label Image

Duloxetine-fig2.jpg (Duloxetine Fig2)

A Kaplan-Meier curve graph showing the proportion of patients with relapse over time (days) from randomization. Two lines represent treatment groups: Duloxetine and Placebo, with the proportion of patients relapsing increasing over time, where the placebo group shows a higher relapse proportion compared to Duloxetine up to about 250 days.*

FDA Label Image

Duloxetine-fig3.jpg (Duloxetine Fig3)

A line graph showing the percentage of patients improved versus percent improvement in pain from baseline. The graph compares four groups: Duloxetine 60 mg BID, Duloxetine 60 mg QD, Duloxetine 20 mg QD, and placebo, with improvement trends decreasing from left to right across increasing pain improvement percentages.*

FDA Label Image

Duloxetine-fig4.jpg (Duloxetine Fig4)

A line graph depicting the percentage of patients improved versus percent improvement in pain from baseline for Duloxetine 60 mg BID, Duloxetine 60 mg QD, and placebo. The x-axis shows percent improvement in pain from >0 to 100, and the y-axis shows percentage of patients improved from 0 to 100. Duloxetine groups show higher patient improvement than placebo, with data points connected by lines and a legend distinguishing the three groups.*

FDA Label Image

Duloxetine-fig5.jpg (Duloxetine Fig5)

A line graph depicting the percentage of patients improved relative to percent improvement in pain from baseline. The graph compares three groups: Duloxetine 60 mg twice daily, Duloxetine 60 mg once daily, and placebo. The x-axis represents percent improvement in pain, while the y-axis represents the percentage of patients improved. Duloxetine groups show higher improvement percentages compared to placebo across the range.*

FDA Label Image

Duloxetine-fig6.jpg (Duloxetine Fig6)

A line graph displaying the percentage of patients improved versus percent improvement in pain from baseline. It compares duloxetine at 120 mg once daily, 60 mg once daily, and 20 mg once daily against placebo. The graph shows trends of pain improvement across different dosage levels of duloxetine and placebo over the percentage scale.*

FDA Label Image

Figure 7 (Duloxetine Fig7)

A line graph comparing the percentage of patients improved versus percent improvement in pain from baseline for Duloxetine 60 mg once daily and placebo. The x-axis shows percent improvement in pain from 0 to 100%, and the y-axis shows the percentage of patients improved from 0 to 100%. Two curves represent patients taking Duloxetine and placebo, illustrating differences in improvement rates at various pain reduction thresholds.*

FDA Label Image

Duloxetine-fig8.jpg (Duloxetine Fig8)

A dose-response curve chart comparing the percentage of patients improved versus percent improvement in pain from baseline (BOCF) between placebo and Duloxetine 60/120 mg once daily groups. The chart shows higher improvement percentages for Duloxetine across different pain improvement levels.*

FDA Label Image

Duloxetine-fig9.jpg (Duloxetine Fig9)

A line graph comparing the percentage of patients improved in pain over various percent improvements from baseline. It shows two lines: one for placebo and one for duloxetine 60 mg once daily, with the duloxetine line consistently higher, indicating greater patient improvement.*

FDA Label Image

Duloxetine-fig10.jpg (Duloxetine Fig10)

A line graph comparing percentage of patients improved versus percent improvement in pain from baseline for Duloxetine 60/120 mg once daily and placebo. The vertical axis shows the percentage of patients improved (0-100%), and the horizontal axis shows percent improvement in pain (0-100%). Two lines represent Duloxetine and placebo with Duloxetine showing higher patient improvement across pain improvement percentages.*

FDA Label Image

30 Capsules (Duloxetine 20 mg)

Label for DULOXETINE HYDROCHLORIDE delayed-release capsules USP, 20 mg strength, by Alembic Pharmaceuticals Inc. The label indicates 30 capsules per container with prescription-only status. It includes dosage strength information, manufacturer details, and a barcode. The label advises dispensing the accompanying Medication Guide and storage instructions.*

FDA Label Image

30 Capsules (Duloxetine 30 mg)

Label for Duloxetine delayed-release capsules USP, 30 mg, by Alembic Pharmaceuticals Inc. The label includes dosage information, manufacturer details, NDC 62332-279-30, and a barcode. It specifies 30 capsules per container and includes handling instructions such as child resistance, storage conditions, and a warning not to use if the inner seal is broken.*

FDA Label Image

30 Capsules (Duloxetine 60 mg)

DULOXETINE HYDROCHLORIDE delayed-release capsules USP, 60 mg strength, in a package of 30 capsules by Alembic Pharmaceuticals Inc. The label includes the NDC 62332-280-30 and instructions to dispense with an accompanying medication guide. It indicates the product is Rx only and provides manufacturer details and storage instructions.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.